MapLight Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-09-19. It has amended it 2 times. As of its latest filing, on 2026-09-18, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on the Nasdaq Global Select Market under the symbol “MPLT.” On September 17, 2026, the last reported sale price for our common stock on the Nasdaq Global Select Market was $11.32 per share.From the S-1/A filed 2026-09-18
Shares offered
We are offering 14,750,000 shares of our common stock.From the S-1/A filed 2025-10-06
Use of proceeds
We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash, cash equivalents and short-term investments, to advance the clinical development of our current programs, to fund research and development activities for additional programs, and for working capital and other general corporate purposes.From the S-1/A filed 2025-10-06
Net loss or income
For the years ended December 31, 2024 and 2023 and for the six months ended June 30, 2025, our net losses were $77.6 million, $55.7 million and $52.2 million, respectively.From the S-1/A filed 2025-10-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-09-19 | Registration statement filed | S-1 |
| 2025-10-06 | Registration statement amended | S-1/A |
| 2026-09-09 | Registration statement filed | S-1 |
| 2026-09-18 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for MapLight Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.